Glycemic control and complications in glycogen storage disease type I: Results from the Swiss registry.

Kaiser, Nathalie; Gautschi, Matthias; Bosanska, Lenka; Meienberg, Fabian; Baumgartner, Matthias R; Spinas, Giatgen A; Hochuli, Michel (2019). Glycemic control and complications in glycogen storage disease type I: Results from the Swiss registry. Molecular genetics and metabolism, 126(4), pp. 355-361. Elsevier 10.1016/j.ymgme.2019.02.008

[img] Text
Unbenannt.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (466kB) | Request a copy

BACKGROUND Regular carbohydrate intake to avoid hypoglycemia is the mainstay of dietary treatment in glycogen storage disease type I (GSDI). The aim of this study was to evaluate the quality of dietary treatment and glycemic control in a cohort of GSDI patients, in relation to the presence of typical long-term complications. METHODS Data of 25 patients (22 GSD subtype Ia and 3 GSDIb, median age 20y) from the Swiss hepatic glycogen storage disease registry was analyzed cross-sectionally. Frequency and type of hypoglycemia symptoms were assessed prospectively using a structured questionnaire. Diagnostic continuous glucose monitoring (CGM) was performed as part of usual clinical care to assess glycemic control in 14 patients, usually once per year with a mean duration of 6.2 ± 1.1 consecutive days per patient per measurement. RESULTS Although maintenance of euglycemia is the primary goal of dietary treatment, few patients (n = 3, 13%) performed capillary blood glucose measurements regularly. Symptoms possibly associated with hypoglycemia were present in 13 patients (57%), but CGM revealed periods of low glucose (<4 mmol/l) in all patients, irrespective of the presence of symptoms. GSDIa patients with liver adenomas (n = 9, 41%) showed a higher frequency and area under the curve (AUC) of low blood glucose than patients without adenomas (frequency 2.7 ± 0.8 vs. 1.5 ± 0.7 per day, AUC 0.11 ± 0.08 vs. 0.03 ± 0.02 mmol/l/d; p < 0.05). Similarly, the presence of microalbuminuria was also associated with the frequency of low blood glucose. Z-Scores of bone density correlated negatively with lactate levels. CONCLUSION The quality of glucose control is related to the presence of typical long-term complications in GSDI. Many patients experience episodes of asymptomatic low blood glucose. Regular assessment of glucose control is an essential element to evaluate the quality of treatment, and increasing the frequency of glucose self-monitoring remains an important goal of patient education and motivation. CGM devices may support patients to optimize dietary therapy in everyday life.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine

UniBE Contributor:

Gautschi, Matthias

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1096-7192

Publisher:

Elsevier

Language:

English

Submitter:

Alexandra Müller

Date Deposited:

03 Jan 2020 13:51

Last Modified:

03 Jan 2020 13:51

Publisher DOI:

10.1016/j.ymgme.2019.02.008

PubMed ID:

30846352

Uncontrolled Keywords:

Adenoma Bone CGM GSD Glucose Glycogen storage disease Nephropathy

BORIS DOI:

10.7892/boris.136910

URI:

https://boris.unibe.ch/id/eprint/136910

Actions (login required)

Edit item Edit item
Provide Feedback